No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Pleuromutilin is a class of antibiotics used to treat bacterial infections. It is a semi-synthetic derivative of the natural product tiamulin, which is produced by Streptomyces species. Pleuromutilin antibiotics are effective against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). They are also active against some anaerobic bacteria and mycoplasma. Pleuromutilin antibiotics are generally well tolerated and have a low risk of adverse effects.
The pleuromutilin market is a rapidly growing segment of the global antibiotics market. It is driven by the increasing prevalence of antibiotic-resistant bacteria, as well as the need for more effective and safer antibiotics. The market is expected to continue to grow in the coming years, as new pleuromutilin-based drugs are developed and approved.
Some companies in the pleuromutilin market include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more
